Striatum and Hippocampus on Different Time Scales
e-Time
Role of the Striatum and Hippocampus on Different Time Scales
2 other identifiers
interventional
104
1 country
1
Brief Summary
Time processing is fundamental to survival and goal reaching in humans. Different time scales (seconds, minutes, and beyond) are processed through specific cognitive processes involving different neural representations. It is generally agreed that time scale in seconds-to-minutes range named "interval timing" would be anatomically linked to the striatum. Indeed, it is possible to demonstrate a deficit of interval timing processes in patients suffering from striatal damage (Huntington's disease). However, recent findings show involvement of a second brain structure, the hippocampus, in interval timing processing in the minutes range, suggesting an interaction between the striatum and hippocampus. Presumably, patients with hippocampal damage (Alzheimer's disease) would specifically show a decrease in performance for this minutes-range time scale. This study aims to provide a better understanding of the role of the striatum in the treatment of time and its interactions with other brain structures such as the hippocampus. More specifically, it is unclear whether the striatum plays a platform role that would always be involved regardless of the time scale, as suggested by the unified model of time or whether different brain structures is solicited according to the time scale, as suggested by the modular system model. In order to elucidate these issues, a potential double dissociation between brain structures and time scales will be tested.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jan 2023
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 4, 2022
CompletedStudy Start
First participant enrolled
January 6, 2023
CompletedFirst Posted
Study publicly available on registry
July 12, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
March 30, 2026
CompletedJuly 12, 2023
July 1, 2023
2.2 years
March 4, 2022
July 5, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Ability to discriminate durations
Ability to discriminate durations of a few seconds and durations of the order of minutes
25 months and 10 days
Secondary Outcomes (2)
Risks's prediction of temporal disorientation.
26 months
Identification of neural correlations with temporal perception tests
27 months
Study Arms (3)
Patients carrying the Huntington's gene
EXPERIMENTALA "long" temporal perception task and a "short" temporal perception task
Alzheimer's disease patients
EXPERIMENTALA "long" temporal perception task and a "short" temporal perception task
Healthy Volunteers
ACTIVE COMPARATORA "long" temporal perception task and a "short" temporal perception task
Interventions
A "long" temporal perception task in which the duration of the stimulus, around 2 min, is materialized by a video. For each trial, two videos are displayed to the participants, and then the task of the participant is to indicate the longest video and to give his level of confidence in his answer. A "short" temporal perception task which will take place in the same way as the "long" task except that the duration of the stimulus, around 2 seconds, is materialized by still frames from the videos used in the previous task.
Eligibility Criteria
You may qualify if:
- Huntington's disease gene carriers
- Patient included in the BioHD protocol
- Age from 18 to 90 years old
- Symptomatic patient
- TFC ≥ 11
- UHDRS motor\> 5
- Native language: French
- Affiliation to a social security or to another social protection
- Signature of informed consent
- Patients with Alzheimer's disease
- MMS from 20 to 26 (included)
- Age: from 60 to 90 years old
- Native language: French
- Progressive deterioration of memory reported by patient or caregiver for more than 6 months
- Profile at RL /RI 16: no significant improvement with indexing
- +11 more criteria
You may not qualify if:
- Huntington's disease gene carriers
- Intellectual deterioration preventing understanding of the protocol
- Other dementia than Huntington's disease
- Patient living alone at home
- Major depression
- Patient under legal protection
- Patient deprived of liberty
- Pregnant or breastfeeding woman, situation known to the investigator
- Inability to handle an electronic tablet
- Patients with Alzheimer's disease
- Intellectual deterioration preventing understanding of the protocol
- Patient living alone at home
- Sudden onset of memory impairment
- Early onset of the following symptoms: difficulty in walking, convulsions, changes in behavior
- Focal neurological characteristics including hemiparesis, sensory loss, visual field deficit
- +16 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Assistance Publique Hôpitaux de Paris - Hôpital Henri Mondor
Créteil, 94010, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Anne-Catherine BACHOUD-LEVI, MD, PhD
Assistance Publique - Hôpitaux de Paris
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 4, 2022
First Posted
July 12, 2023
Study Start
January 6, 2023
Primary Completion
March 30, 2025
Study Completion
March 30, 2026
Last Updated
July 12, 2023
Record last verified: 2023-07